hoe-777 and Eczema

In an open multi-center study on 1,286 patients aged 60 years and more, we tested the efficacy and compatibility of prednicarbate (Dermatop) in various vehicles. The eczemas and erythematosquamous dermatoses of 857 patients (66.6%) disappeared within three weeks treatment. In 142 patients (11%), it took more than 3 weeks (62 day at the most) to achieve a complete healing. A very good or good tolerance was observed in 97.1% of the patients. Only in 1.5% the study had to be broken off because of a change for the worse. Prednicarbate, therefore, is especially suitable in the treatment of eczemas and chronic erythematosquamous dermatoses of aged skin.

Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis; Eczema; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pharmaceutical Vehicles; Prednisolone; Skin Aging

After a brief account of the therapeutic problems with microbially superinfected eczemas, the results of a double-blind study of hospitalized patients are reported. Two concentrations of the antibacterial agent Bardac-22 (didecyl-dimethyl-ammonium chloride. Hoe S 2922) in combination with the steroid prednicarbate (prednisolone 17-(ethylcarbonate)-21-propionate, Hoe 777) were used. The quantitative determination of cutaneous bacteria was performed by a modified method of Faergemann. The double blind study did not reveal any significant differences in effectiveness, although a trend in favour of the higher concentration was apparent.

Topics: Anti-Infective Agents, Local; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Infections; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Eczema; Female; Humans; Impetigo; Male; Middle Aged; Prednisolone; Quaternary Ammonium Compounds

We report on the results of an openly conducted multicenter study concerning efficacy and tolerance of a new prednisolone derivative free from halogenic groups (prednicarbate 0.25%, Dermatop) prepared as a) emulsifiable greasy ointment without water, b) w/o emulsion (ointment), and c) o/w emulsion (cream). These preparations were therapeutically applied in eczema (allergic, seborrheic, microbic), psoriasis, and atopic dermatitis. The study was carried out in close team work between a clinic and 37 practicing dermatologists and included 383 patients. After 3 weeks therapy, 4% of the patients did not reveal any satisfying results; 16% showed medium outcome with some persisting symptoms; in 80% of the patients, we observed good to very good therapeutic results.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Berlin; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis; Dermatitis, Atopic; Dermatitis, Seborrheic; Eczema; Female; Humans; Male; Middle Aged; Pharmaceutical Vehicles; Prednisolone; Psoriasis

Two female patients developed an allergic contact dermatitis after using Dermatop cream and -ointment for several weeks. Patch tests were positive with the reagent prednicarbate itself. No cross reactions to other glucocorticosteroids were observed. Type-IV-sensitization to glucocorticosteroids should be considered if chronic dermatitis does not improve, or even becomes worse, in spite of adequate therapy. With regard to possible cross reactions or multiple sensitization, epicutaneous tests with other glucocorticosteroids are necessary.

Topics: Adolescent; Aged; Anti-Inflammatory Agents; Dermatitis, Contact; Eczema; Female; Humans; Prednisolone; Skin Tests

Prednicarbate (Dermatop) was topically applied in 50 children suffering from inflammatory dermatoses. In 12 children, the courses of therapy were documented by photographs. Its rapid onset of action, its lacking suppression of the endogenic biosynthesis of cortisol, as well as its small antiproliferative effect on cutaneous fibroblasts suggest that prednicarbate bears only minor risks especially for children's skin.

Topics: Administration, Topical; Anti-Inflammatory Agents; Child; Child, Preschool; Dermatitis; Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Eczema; Female; Humans; Male; Prednisolone

In 20 patients suffering from acute or chronic inflammatory dermatoses, topical treatment with prednicarbate (Dermatop) was photographically documented and evaluated. Because of the rapid and pronounced anti-inflammatory and anti-edematous effect of prednisolone-17-ethyl carbonic ester without halogenic groups, therapy took only 7 to 21 days. Since there was practically no suppression of the endogenic biosynthesis of cortisol and no atrophogenic potency, we expected a minimum of side effects along with a maximum of therapeutic results.

Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Dermatitis; Dermatitis, Atopic; Dermatitis, Contact; Eczema; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prednisolone; Psoriasis